Cemiplimab vs Sasanlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03088540 · Phase 3 · completed

This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.

Next expected readout: December 2026 · NCT06623656 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)

Result source: NCT03088540

Sasanlimab

Developed by Pfizer

Phase 2/3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04181788 · Phase 1/2 · completed

Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.

Reported efficacy

Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms); Phase 2: AUCτ of PF-06801591 at Steady State (Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm); Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 (Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm): Dose-limiting toxicities in phase 1b: 0 participants in each of the four arms (sasanlimab 300 mg SC Q4W escalation and expansion, 600 mg SC Q6W escalation and expansion); no comparator arm. (not_applicable)

Result source: NCT04181788

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemiplimabSasanlimab
PFS, median6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
—Trial running · NCT06218069
OS, median21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
14.7b300 mg SC · n 68NCT02573259
1 other result
  • 10.9 300 mg SC · n 39 · Phase 1 · secondary NCT02573259
ORR43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
16.4%b300 mg SC · n 67NCT02573259
3 other results
  • 18.4% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
  • 19.4% 300 mg SC · n 67 · Phase 1 · primary NCT02573259
  • 21.1% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
Duration of response, median16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
—Trial running · NCT06218069

PFS, median

Cemiplimab
6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
Sasanlimab
—Trial running · NCT06218069

OS, median

Cemiplimab
21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
Sasanlimab
14.7b300 mg SC · n 68NCT02573259
1 other result
  • 10.9 300 mg SC · n 39 · Phase 1 · secondary NCT02573259

ORR

Cemiplimab
43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
Sasanlimab
16.4%b300 mg SC · n 67NCT02573259
3 other results
  • 18.4% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
  • 19.4% 300 mg SC · n 67 · Phase 1 · primary NCT02573259
  • 21.1% 300 mg SC · n 38 · Phase 1 · primary NCT02573259

Duration of response, median

Cemiplimab
16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
Sasanlimab
—Trial running · NCT06218069
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cemiplimab: 4 of 4 rows · Sasanlimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimabSasanlimab
Dropout rate
79%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
90.7%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
90.1%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone600 mg SC Q6Wa
NCT04181788 · Phase 1/2
show 12 more results
n/a: no completion milestone600 mg SC Q6W
NCT04181788 · Phase 1/2
n/a: no completion milestone600 mg SC Q6W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
86.7%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
85.3%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
87.2%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
85.7%10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
75%3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
100%1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
50%0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
0.3%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
0%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
0.3%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
—30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
16.7%600 mg SC Q6Wa
NCT04181788 · Phase 1/2
show 12 more results
0%600 mg SC Q6W
NCT04181788 · Phase 1/2
3.8%600 mg SC Q6W
NCT04181788 · Phase 1/2
0%300 mg SC Q4W
NCT04181788 · Phase 1/2
16.7%300 mg SC Q4W
NCT04181788 · Phase 1/2
2.4%300 mg SC Q4W
NCT04181788 · Phase 1/2
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Serious AEs
36.8%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
27.1%Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
35.2%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
30.4%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
33.3%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%600 mg SC Q6Wa
NCT04181788 · Phase 1/2
show 12 more results
0%600 mg SC Q6W
NCT04181788 · Phase 1/2
16.3%600 mg SC Q6W
NCT04181788 · Phase 1/2
25%300 mg SC Q4W
NCT04181788 · Phase 1/2
16.7%300 mg SC Q4W
NCT04181788 · Phase 1/2
39%300 mg SC Q4W
NCT04181788 · Phase 1/2
20%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
26.5%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
34.2%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
42.9%10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
37.5%3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
37.5%1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
50%0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
anaemia 19.7%
decreased appetite 13.8%
fatigue 13.5%
NCT03088540 · Phase 3
show 10 more results
anaemia 31.8%
alopecia 22.4%
diarrhoea 18.8%
NCT03088540 · Phase 3 · combination
anaemia 48.1% (placebo 39.9%)
neutropenia 28.7% (placebo 12.4%)
alopecia 27.8% (placebo 43.8%)
NCT03409614 · Phase 3 · combination
anaemia 33.9% (placebo 39.9%)
nausea 28.4% (placebo 16.3%)
fatigue 21.1% (placebo 8.5%)
NCT03409614 · Phase 3 · combination
anaemia 44.2% (placebo 39.9%)
alopecia 37.5% (placebo 43.8%)
nausea 25.3% (placebo 16.3%)
NCT03409614 · Phase 3 · combination
30 mg/kg
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
600 mg SC Q6Wa
pruritus 50%
alanine aminotransferase increased 16.7%
alopecia 16.7%
NCT04181788 · Phase 1/2
show 12 more results
600 mg SC Q6W
anaemia 50%
blood glucose increased 33.3%
blood bilirubin increased 25%
NCT04181788 · Phase 1/2
600 mg SC Q6W
dyspnoea 13.8%
anaemia 12.5%
weight decreased 12.5%
NCT04181788 · Phase 1/2
300 mg SC Q4W
alanine aminotransferase increased 25%
anaemia 25%
aspartate aminotransferase increased 25%
NCT04181788 · Phase 1/2
300 mg SC Q4W
anaemia 33.3%
hypertriglyceridaemia 33.3%
hypoalbuminaemia 33.3%
NCT04181788 · Phase 1/2
300 mg SC Q4W
asthenia 22%
dyspnoea 22%
anaemia 19.5%
NCT04181788 · Phase 1/2
300 mg SC
decreased appetite 46.7%
nausea 40%
dyspnoea 33.3%
NCT02573259 · Phase 1 · registry result, not featured evidence
300 mg SC
anaemia 19.1%
dyspnoea 14.7%
decreased appetite 13.2%
NCT02573259 · Phase 1 · registry result, not featured evidence
300 mg SC
anaemia 31.6%
asthenia 15.8%
back pain 15.8%
NCT02573259 · Phase 1 · registry result, not featured evidence
10 mg/kg IV
generalised oedema 57.1%
constipation 42.9%
aspartate aminotransferase increased 28.6%
NCT02573259 · Phase 1 · registry result, not featured evidence
3 mg/kg IV
generalised oedema 50%
arthralgia 37.5%
blood thyroid stimulating hormone increased 37.5%
NCT02573259 · Phase 1 · registry result, not featured evidence
1 mg/kg IV
constipation 50%
decreased appetite 37.5%
generalised oedema 37.5%
NCT02573259 · Phase 1 · registry result, not featured evidence
0.5 mg/kg IV
back pain 100%
blood creatinine increased 100%
constipation 100%
NCT02573259 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cemiplimab

Overall Survival 23.4 vs 13.7 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
15.9 vs 13.9 Chemotherapy months
NCT03409614 · Phase 3 · combination
20.1 vs 13.9 Chemotherapy months
NCT03409614 · Phase 3 · combination
21.1 vs 12.9 placebo months
NCT03409614 · Phase 3 · combination
PFS 6.3 vs 5.3 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
6.5 vs 6.4 Chemotherapy months
NCT03409614 · Phase 3 · combination
6.4 vs 6.4 Chemotherapy months
NCT03409614 · Phase 3 · combination
8.2 vs 5.5 placebo months
NCT03409614 · Phase 3 · combination
ORR 42.3% (n=357) vs 21.4% (n=355) Chemotherapy
responder rate · % of participants
NCT03088540 · Phase 3
show 3 more results
40.7% (n=108) vs 28.3% (n=106) Chemotherapy
NCT03409614 · Phase 3 · combination
36.7% (n=109) vs 28.3% (n=106) Chemotherapy
NCT03409614 · Phase 3 · combination
43.6% (n=312) vs 22.1% (n=154) placebo
NCT03409614 · Phase 3 · combination
Duration of Response 24.1 vs 5.9 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
7.8 vs 6.2 Chemotherapy months
NCT03409614 · Phase 3 · combination
15.9 vs 6.2 Chemotherapy months
NCT03409614 · Phase 3 · combination
16.4 vs 7.3 placebo months
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 4.92 vs 0.45 Chemotherapy score @ 3wk
absolute change · score
Cycle 2, Day 1 (C2D1)
NCT03088540 · Phase 3
show 2 more results
2.13 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
1.58 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 7.23 vs 1.25 Chemotherapy score @ 6wk
absolute change · score
C3D1
NCT03088540 · Phase 3
show 3 more results
4.65 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
2.75 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
0.96 vs 2.8 placebo score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.13 vs 2.43 Chemotherapy score @ 9wk
absolute change · score
C4D1
NCT03088540 · Phase 3
show 3 more results
6.22 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
3 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
1.92 vs 4.09 placebo score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.27 vs 1.88 Chemotherapy score @ 12wk
absolute change · score
C5D1
NCT03088540 · Phase 3
show 3 more results
3.31 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
4.72 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
3.35 vs 2.28 placebo score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 9.64 vs 3 Chemotherapy score @ 15wk
absolute change · score
C6D1
NCT03088540 · Phase 3
show 3 more results
5.63 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.38 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.42 vs 2.89 placebo score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.19 vs 2.55 Chemotherapy score @ 24wk
absolute change · score
C9D1
NCT03088540 · Phase 3
show 3 more results
6.87 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
1.8 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
3.65 vs 2.02 placebo score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 11.11 vs -4.17 Chemotherapy score @ 33wk
absolute change · score
C12D1
NCT03088540 · Phase 3
show 3 more results
4.44 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
9.15 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
2.37 vs 3.54 placebo score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.88 vs 5.36 Chemotherapy score @ 42wk
absolute change · score
C15D1
NCT03088540 · Phase 3
show 3 more results
7.35 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
9.4 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
6.23 vs 6.61 placebo score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination

+ 40 further endpoints in the CSV export.

Sasanlimab

ORR 16.4% (n=67)300 mg SC
responder rate · % of participants
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 3 more results
18.4% (n=38)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
19.4% (n=67)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
21.1% (n=38)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
ORR 6.7% (n=15)300 mg SC
event count · % of participants
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 9 more results
6.7% (n=15)*300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
28.6% (n=7)*10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=7)*10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
12.5% (n=8)*3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
12.5% (n=8)*3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
28.6% (n=7)*1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=7)*1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
50% (n=2)*0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
50% (n=2)*0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
PFS 3 months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 2 more results
3.7 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
2.9 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Duration of Response NA months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 2 more results
21.8 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
13.9 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Time to Response 2.71 months300 mg SC
time to event · months
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
2.33 months300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
Time to Progression 3.7 months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
3.7 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Overall Survival 14.7 months300 mg SC
time to event · months
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
10.9 months300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
Overall Survival 0.773 Probability @ 26wk300 mg SC
absolute value · Probability
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 5 more results
0.711 Probability @ 26wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.547 Probability @ 52wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.471 Probability @ 52wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.403 Probability @ 104wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.286 Probability @ 104wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Sasanlimab's landscape